search
Back to results

Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia (AML-17)

Primary Purpose

Leukemia

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
cytarabine
etoposide
gemtuzumab ozogamicin
idarubicin
mitoxantrone hydrochloride
Sponsored by
European Organisation for Research and Treatment of Cancer - EORTC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring adult acute monocytic leukemia (M5b), adult acute erythroid leukemia (M6), adult acute megakaryoblastic leukemia (M7), adult acute minimally differentiated myeloid leukemia (M0), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult acute monoblastic leukemia (M5a), untreated adult acute myeloid leukemia, secondary acute myeloid leukemia, adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22)

Eligibility Criteria

61 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) Bone marrow blasts at least 20% by bone marrow aspiration or biopsy FAB subtypes M0-M2 and M4-M7 No acute promyelocytic leukemia (FAB subtype M3) Previously untreated primary or secondary AML, including AML after myelodysplastic syndromes Hydroxyurea and/or corticosteroid therapy for no more than 14 days allowed No blast crisis of chronic myelogenous leukemia No AML supervening after other myeloproliferative diseases No active CNS leukemia PATIENT CHARACTERISTICS: Age 61 to 75 Performance status WHO 0-2 Life expectancy Not specified Hematopoietic WBC less than 30,000/mm^3 (pretreatment with hydroxyurea for no more than 14 days allowed) Hepatic Bilirubin no greater than 3 times upper limit of normal (ULN) Renal Creatinine no greater than 3 times ULN Cardiovascular No concurrent severe cardiovascular disease No arrhythmias requiring chronic treatment No congestive heart failure No symptomatic ischemic heart disease Pulmonary No severe pulmonary dysfunction (CTC grade 3-4) Other HIV negative No other uncontrolled infection No other concurrent malignant disease No severe concurrent neurological or psychiatric disease No prior alcohol abuse No psychological, familial, sociological, or geographical condition that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent hematopoietic growth factors (filgrastim [G-CSF] or sargramostim [GM-CSF]) except for life-threatening infection due to neutropenia Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics Radiotherapy Not specified Surgery Not specified Other No prior enrollment in this trial

Sites / Locations

  • A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung
  • Allgemeines Krankenhaus - Universitatskliniken
  • AZ Sint-Jan
  • Institut Jules Bordet
  • Hopital Universitaire Erasme
  • Centre Hospitalier Universitaire Brugmann
  • Universitair Ziekenhuis Antwerpen
  • Hopital de Jolimont
  • CHU Liege - Domaine Universitaire du Sart Tilman
  • Centre Hospitalier Peltzer-La Tourelle
  • Hopital Edouard Herriot
  • Centre Antoine Lacassagne
  • Hotel Dieu de Paris
  • Klinikum der Albert - Ludwigs - Universitaet Freiburg
  • Ruprecht - Karls - Universitaet Heidelberg
  • Southwest German Cancer Center at Eberhard-Karls-University
  • Universita Degli Studi di Bari
  • Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi
  • Azienda Sanitaria di Bolzano
  • Ospedale Binaghi
  • Ospedale Oncologico A. Businco
  • Ospedale Ferrarotto
  • Ospedale Regionale A. Pugliese
  • Azienda Istituti Ospitalieri
  • Universita di Ferrara
  • Ospedale S. Antonio Abate
  • Ospedale San Martino
  • Universita degli Studi di Messina
  • Azienda Ospedaliera Papardo
  • Ospedale Civile Umberto I
  • Azienda Ospedaliera - Universitaria di Modena
  • Azienda Ospedaliera "A. Cardarelli"
  • Federico II University Medical School
  • Azienda Ospedaliera Maggiore Della Carita
  • Azienda Ospedale S. Luigi at University of Torino
  • Azienda Ospedaliera Policlinico Paolo Giaccone
  • Ospedale Cervello
  • Ospedale La Maddalena - Palermo
  • Perugia Regional Cancer Center
  • Azienda Ospedale - d "S. Salvatore"
  • Ospedale Civile Pescara
  • Ospedale Sant' Eugenio
  • Libero Istituto Universitario Campus Bio-Medico
  • Universita Degli Studi "La Sapeinza"
  • Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore
  • H. San Giovanni-Addolorata Hospital
  • Istituto di Ematologia Universita - University di Sassari
  • Policlinico G. B. Rossi - Borgo Roma
  • Ospedale San Bortolo
  • Jeroen Bosch Ziekenhuis
  • Onze Lieve Vrouwe Gasthuis
  • Leiden University Medical Center
  • Universitair Medisch Centrum St. Radboud - Nijmegen
  • Maxima Medisch Centrum - Veldhoven
  • Hospital Escolar San Joao

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ARM A

ARM B

Arm Description

GO + MICE for remission induction followed by GO + mini-ICE for consolidation

MICE for remission induction followed by mini-ICE for consolidation

Outcomes

Primary Outcome Measures

Overall survival

Secondary Outcome Measures

Response (complete remission [CR] or complete remission with incomplete recovery of platelet count [CRp]) rate after induction
Disease-free survival after CR/CRp
Incidence of relapse after CR/CRp
Incidence of death without relapse after CR/CRp
Event-free survival
Toxicity (highest grade) assessed by International Working Group CTC v2.0

Full Information

First Posted
January 24, 2003
Last Updated
August 24, 2012
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
search

1. Study Identification

Unique Protocol Identification Number
NCT00052299
Brief Title
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
Acronym
AML-17
Official Title
Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
September 2002 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
February 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto

4. Oversight

5. Study Description

Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known if combining combination chemotherapy with monoclonal antibody therapy will kill more cancer cells. PURPOSE: Randomized phase III trial to determine the effectiveness of combination chemotherapy with or without gemtuzumab ozogamicin in treating patients who have acute myeloid leukemia.
Detailed Description
OBJECTIVES: Determine the antileukemic activity of standard induction chemotherapy with or without gemtuzumab ozogamicin in elderly patients with previously untreated acute myeloid leukemia. Determine the overall survival of patients treated with these regimens. Determine the rate of response, disease-free survival, event-free survival, incidence of relapse, and incidence of death of patients treated with these regimens. Determine the rate, type, and grade of toxicity of these regimens in these patients. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to age (61-69 vs 70-75), CD33 positivity (less than 5% vs 5-19% vs 20-80% vs more than 80% vs unknown), initial WBC before hydroxyurea administration if needed (less than 30,000/mm^3 vs at least 30,000/mm^3), and participating center. Patients are randomized to 1 of 2 treatment arms. Arm I: Induction (phase I): Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Induction (phase II/MICE regimen): Beginning between days 50 and 53, patients receive mitoxantrone IV over 30 minutes on days 1, 3, and 5; etoposide IV over 1 hour on days 1-3; and cytarabine IV continuously on days 1-7. Bone marrow evaluation is performed on day 29. Patients with partial remission (PR) receive a second course of MICE chemotherapy regimen. Patients with complete remission (CR) after 1 or 2 courses of MICE regimen proceed to consolidation therapy. Patients with progressive disease go off therapy. Consolidation: Beginning within 4 weeks of documentation of CR, patients receive gemtuzumab ozogamicin IV over 2 hours on day 0; idarubicin IV on days 1, 3, and 5; etoposide IV over 1 hour on days 1-3; and cytarabine IV continuously on days 1-5. After at least day 30, patients receive a second consolidation course in the absence of disease progression or unacceptable toxicity. Arm II: Induction (MICE regimen): Patients receive mitoxantrone, etoposide, and cytarabine as in arm I induction. Bone marrow evaluation is performed on day 29. Patients with PR receive a second course of MICE chemotherapy regimen. Patients with CR after 1 or 2 courses of MICE regimen proceed to consolidation therapy. Patients with progressive disease go off therapy. Consolidation: Patients receive idarubicin, etoposide, and cytarabine as in arm I consolidation. Patients are followed monthly for 1 year, every 3 months for 2 years, and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 450 patients (225 per treatment arm) will be accrued for this study within 3.75 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
Keywords
adult acute monocytic leukemia (M5b), adult acute erythroid leukemia (M6), adult acute megakaryoblastic leukemia (M7), adult acute minimally differentiated myeloid leukemia (M0), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult acute monoblastic leukemia (M5a), untreated adult acute myeloid leukemia, secondary acute myeloid leukemia, adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
472 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ARM A
Arm Type
Experimental
Arm Description
GO + MICE for remission induction followed by GO + mini-ICE for consolidation
Arm Title
ARM B
Arm Type
Active Comparator
Arm Description
MICE for remission induction followed by mini-ICE for consolidation
Intervention Type
Drug
Intervention Name(s)
cytarabine
Intervention Type
Drug
Intervention Name(s)
etoposide
Intervention Type
Drug
Intervention Name(s)
gemtuzumab ozogamicin
Intervention Type
Drug
Intervention Name(s)
idarubicin
Intervention Type
Drug
Intervention Name(s)
mitoxantrone hydrochloride
Primary Outcome Measure Information:
Title
Overall survival
Secondary Outcome Measure Information:
Title
Response (complete remission [CR] or complete remission with incomplete recovery of platelet count [CRp]) rate after induction
Title
Disease-free survival after CR/CRp
Title
Incidence of relapse after CR/CRp
Title
Incidence of death without relapse after CR/CRp
Title
Event-free survival
Title
Toxicity (highest grade) assessed by International Working Group CTC v2.0

10. Eligibility

Sex
All
Minimum Age & Unit of Time
61 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) Bone marrow blasts at least 20% by bone marrow aspiration or biopsy FAB subtypes M0-M2 and M4-M7 No acute promyelocytic leukemia (FAB subtype M3) Previously untreated primary or secondary AML, including AML after myelodysplastic syndromes Hydroxyurea and/or corticosteroid therapy for no more than 14 days allowed No blast crisis of chronic myelogenous leukemia No AML supervening after other myeloproliferative diseases No active CNS leukemia PATIENT CHARACTERISTICS: Age 61 to 75 Performance status WHO 0-2 Life expectancy Not specified Hematopoietic WBC less than 30,000/mm^3 (pretreatment with hydroxyurea for no more than 14 days allowed) Hepatic Bilirubin no greater than 3 times upper limit of normal (ULN) Renal Creatinine no greater than 3 times ULN Cardiovascular No concurrent severe cardiovascular disease No arrhythmias requiring chronic treatment No congestive heart failure No symptomatic ischemic heart disease Pulmonary No severe pulmonary dysfunction (CTC grade 3-4) Other HIV negative No other uncontrolled infection No other concurrent malignant disease No severe concurrent neurological or psychiatric disease No prior alcohol abuse No psychological, familial, sociological, or geographical condition that would preclude study participation PRIOR CONCURRENT THERAPY: Biologic therapy No concurrent hematopoietic growth factors (filgrastim [G-CSF] or sargramostim [GM-CSF]) except for life-threatening infection due to neutropenia Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics Radiotherapy Not specified Surgery Not specified Other No prior enrollment in this trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sergio Amadori, MD
Organizational Affiliation
Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma
Official's Role
Study Chair
Facility Information:
Facility Name
A. oe. Krankenhaus der Barmherzigen Schwestern Kinderabteilung
City
Linz
ZIP/Postal Code
4010
Country
Austria
Facility Name
Allgemeines Krankenhaus - Universitatskliniken
City
Vienna
ZIP/Postal Code
A-1090
Country
Austria
Facility Name
AZ Sint-Jan
City
Brugge
ZIP/Postal Code
8000
Country
Belgium
Facility Name
Institut Jules Bordet
City
Brussels
ZIP/Postal Code
1000
Country
Belgium
Facility Name
Hopital Universitaire Erasme
City
Brussels
ZIP/Postal Code
1070
Country
Belgium
Facility Name
Centre Hospitalier Universitaire Brugmann
City
Brussels
ZIP/Postal Code
B 1020
Country
Belgium
Facility Name
Universitair Ziekenhuis Antwerpen
City
Edegem
ZIP/Postal Code
B-2650
Country
Belgium
Facility Name
Hopital de Jolimont
City
Haine Saint Paul
ZIP/Postal Code
7100
Country
Belgium
Facility Name
CHU Liege - Domaine Universitaire du Sart Tilman
City
Liege
ZIP/Postal Code
B-4000
Country
Belgium
Facility Name
Centre Hospitalier Peltzer-La Tourelle
City
Verviers
ZIP/Postal Code
B-4800
Country
Belgium
Facility Name
Hopital Edouard Herriot
City
Lyon
ZIP/Postal Code
69437
Country
France
Facility Name
Centre Antoine Lacassagne
City
Nice
ZIP/Postal Code
06189
Country
France
Facility Name
Hotel Dieu de Paris
City
Paris
ZIP/Postal Code
75181
Country
France
Facility Name
Klinikum der Albert - Ludwigs - Universitaet Freiburg
City
Freiburg
ZIP/Postal Code
D-79106
Country
Germany
Facility Name
Ruprecht - Karls - Universitaet Heidelberg
City
Heidelberg
ZIP/Postal Code
D-69117
Country
Germany
Facility Name
Southwest German Cancer Center at Eberhard-Karls-University
City
Tuebingen
ZIP/Postal Code
D-72076
Country
Germany
Facility Name
Universita Degli Studi di Bari
City
Bari
ZIP/Postal Code
70124
Country
Italy
Facility Name
Azienda Ospedaliera Di Bologna Policlinico S. Orsola - Malpighi
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
Azienda Sanitaria di Bolzano
City
Bolzano
ZIP/Postal Code
39100
Country
Italy
Facility Name
Ospedale Binaghi
City
Cagliari
ZIP/Postal Code
090100
Country
Italy
Facility Name
Ospedale Oncologico A. Businco
City
Cagliari
ZIP/Postal Code
09121
Country
Italy
Facility Name
Ospedale Ferrarotto
City
Catania
ZIP/Postal Code
95124
Country
Italy
Facility Name
Ospedale Regionale A. Pugliese
City
Catanzaro
ZIP/Postal Code
88100
Country
Italy
Facility Name
Azienda Istituti Ospitalieri
City
Cremona
ZIP/Postal Code
26100
Country
Italy
Facility Name
Universita di Ferrara
City
Ferrara
ZIP/Postal Code
44100
Country
Italy
Facility Name
Ospedale S. Antonio Abate
City
Gallarate Varese
ZIP/Postal Code
21013
Country
Italy
Facility Name
Ospedale San Martino
City
Genoa
ZIP/Postal Code
16132
Country
Italy
Facility Name
Universita degli Studi di Messina
City
Messina
ZIP/Postal Code
98122
Country
Italy
Facility Name
Azienda Ospedaliera Papardo
City
Messina
Country
Italy
Facility Name
Ospedale Civile Umberto I
City
Mestre
ZIP/Postal Code
30174
Country
Italy
Facility Name
Azienda Ospedaliera - Universitaria di Modena
City
Modena
ZIP/Postal Code
41100
Country
Italy
Facility Name
Azienda Ospedaliera "A. Cardarelli"
City
Naples
ZIP/Postal Code
80127
Country
Italy
Facility Name
Federico II University Medical School
City
Naples
ZIP/Postal Code
80131
Country
Italy
Facility Name
Azienda Ospedaliera Maggiore Della Carita
City
Novara
ZIP/Postal Code
28100
Country
Italy
Facility Name
Azienda Ospedale S. Luigi at University of Torino
City
Orbassano
ZIP/Postal Code
10043
Country
Italy
Facility Name
Azienda Ospedaliera Policlinico Paolo Giaccone
City
Palermo
ZIP/Postal Code
90127
Country
Italy
Facility Name
Ospedale Cervello
City
Palermo
ZIP/Postal Code
90146
Country
Italy
Facility Name
Ospedale La Maddalena - Palermo
City
Palermo
Country
Italy
Facility Name
Perugia Regional Cancer Center
City
Perugia
ZIP/Postal Code
06122
Country
Italy
Facility Name
Azienda Ospedale - d "S. Salvatore"
City
Pesaro
ZIP/Postal Code
I-61100
Country
Italy
Facility Name
Ospedale Civile Pescara
City
Pescara
ZIP/Postal Code
65100
Country
Italy
Facility Name
Ospedale Sant' Eugenio
City
Rome
ZIP/Postal Code
00144
Country
Italy
Facility Name
Libero Istituto Universitario Campus Bio-Medico
City
Rome
ZIP/Postal Code
00155
Country
Italy
Facility Name
Universita Degli Studi "La Sapeinza"
City
Rome
ZIP/Postal Code
00161
Country
Italy
Facility Name
Policlinico A. Gemelli - Universita Cattolica del Sacro Cuore
City
Rome
ZIP/Postal Code
00168
Country
Italy
Facility Name
H. San Giovanni-Addolorata Hospital
City
Rome
ZIP/Postal Code
00184
Country
Italy
Facility Name
Istituto di Ematologia Universita - University di Sassari
City
Sassari
ZIP/Postal Code
07100
Country
Italy
Facility Name
Policlinico G. B. Rossi - Borgo Roma
City
Verona
ZIP/Postal Code
37134
Country
Italy
Facility Name
Ospedale San Bortolo
City
Vicenza
ZIP/Postal Code
36100
Country
Italy
Facility Name
Jeroen Bosch Ziekenhuis
City
's-Hertogenbosch
ZIP/Postal Code
5211 NL
Country
Netherlands
Facility Name
Onze Lieve Vrouwe Gasthuis
City
Amsterdam
ZIP/Postal Code
1091 HA
Country
Netherlands
Facility Name
Leiden University Medical Center
City
Leiden
ZIP/Postal Code
2300 CA
Country
Netherlands
Facility Name
Universitair Medisch Centrum St. Radboud - Nijmegen
City
Nijmegen
ZIP/Postal Code
6500 HB
Country
Netherlands
Facility Name
Maxima Medisch Centrum - Veldhoven
City
Veldhoven
ZIP/Postal Code
5500 MB
Country
Netherlands
Facility Name
Hospital Escolar San Joao
City
Porto
ZIP/Postal Code
4200
Country
Portugal

12. IPD Sharing Statement

Citations:
PubMed Identifier
24127442
Citation
Amadori S, Suciu S, Stasi R, Salih HR, Selleslag D, Muus P, De Fabritiis P, Venditti A, Ho AD, Lubbert M, Thomas X, Latagliata R, Halkes CJ, Falzetti F, Magro D, Guimaraes JE, Berneman Z, Specchia G, Karrasch M, Fazi P, Vignetti M, Willemze R, de Witte T, Marie JP. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J Clin Oncol. 2013 Dec 10;31(35):4424-30. doi: 10.1200/JCO.2013.49.0771. Epub 2013 Oct 14.
Results Reference
derived

Learn more about this trial

Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia

We'll reach out to this number within 24 hrs